Miss America 2012 Laura Kaeppler accepts check from Rite Aid for Children’s Miracle Network
NEW YORK — Miss America 2012 Laura Kaeppler was on hand at the Rite Aid store in New York’s Grand Central Terminal Friday to accept a check from the retail pharmacy chain for the Children’s Miracle Network.
Rite Aid’s New York stores raised $348,880 for the Steven and Alexandra Cohen Children’s Medical Center of New York through a Miracle Balloon campaign, including $7,000 raised by the Grand Central store. Rite Aid has been raising money for the organization since 1994.
Also appearing were 11-year-old leukemia survivor Molly Guarton and her grandfather, Bill Hatziyianis, of Long Island. Following the event, Kaeppler signed autographs and posed for photographs with employees, customers and fans.
Kaeppler was announced as the Children’s Miracle Network’s goodwill ambassador shortly after her crowning as Miss America 2012 in January.
CHPA, Partnership at Drugfree.org create DXM-abuse awareness page for teens
WASHINGTON — Making a direct appeal to teens, the Consumer Healthcare Products Association has created the website DXMstories.org that directly engages young adults around the dangers of dextromethorphan abuse with provocative video clips featuring peer anecdotes.
The site shares the effects of DXM abuse along with anecdotal stories from former teen abusers and encourages viewers to "draw your own conclusions about DXM." All information on the site is sourced to medical research, reliable news sources and from people who themselves have abused DXM.
The site is hosted in conjunction with the Partnership at Drugfree.org.
Mylan settles Provigil suit with Teva
PITTSBURGH — Mylan announced that its subsidiary has resolved all disputes with Teva pertaining to the sale of generic versions of a sleep disorder drug.
Under a new agreement with Teva, Mylan Pharmaceuticals is permitted to launch modafinil tablets in the 100-mg and 200-mg strengths, a generic version of Cephalon’s Provigil, prior to the Aug. 10 expiration of a 180-day marketing exclusivity period granted to Teva. As previously reported, Mylan Pharmaceuticals filed a suit in federal court in the District of Columbia against the Food and Drug Administration in relation to Mylan’s abbreviated new drug application for modafinil tablets in the 100-mg and 200-mg strengths.
Other details of the settlement are confidential and the agreement is subject to review by the Department of Justice and the Federal Trade Commission, the companies said.
U.S. sales for modafinil tablets in the 100-mg and 200-mg strengths were $1.2 billion for the 12 months ended in March, according to IMS Health.